drugset / Trial / NCT00703755

A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.

NCT00703755

Phase 2 Completed 2288 enrolled Solvay Pharmaceuticals
RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study was to study the effect of different combinations of fenofibrate and metformin on the cluster of metabolic syndrome (MetS) biochemical abnormalities, and to determine the dose combination allowing normalization of MetS patients.

Timeline

Start
2003-03
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 40 mg
Subject Fenofibrate Small molecule 80 mg
Subject Metformin Small molecule 500 mg
Subject Metformin Small molecule 850 mg

Indications